Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217) in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Latest Information Update: 18 May 2021
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 10 May 2021 Results of pooled analysis assessing clinical pharmacokinetics of oral Semaglutide published in the Clinical Pharmacokinetics.
- 25 Apr 2018 Results assessing pharmacokinetics, safety, and tolerability of oral Semaglutide in subjects with hepatic impairment published in the Journal of Clinical Pharmacology
- 15 Sep 2017 Results assessing pharmacokinetics and tolerability of oral semaglutide in subjects with impaired hepatic function compared to subjects with normal hepatic function, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.